Megace (Megestrol Acetate)

Megestrol acetate binds to progesterone receptors inside cells, influencing gene expression that leads to reduced tumor growth in hormone‑sensitive cancers and increased appetite through central nervous system pathways. This dual action helps both to control disease progression and to counteract weight loss.

The appropriate dose of Megace is determined by the prescribing clinician based on the specific indication, patient weight, disease severity, and response to therapy. Dosage may vary widely, and the prescriber will tailor the regimen to each individual’s clinical needs.

The safety of Megace in pregnancy and lactation has not been established. Because it is a synthetic progestogen, it may affect fetal development or be excreted in breast milk. Healthcare providers usually avoid its use in pregnant or nursing women unless the potential benefit outweighs the risk.

To request Megace, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Compared with other appetite‑stimulating agents such as dronabinol or mirtazapine, Megace offers both appetite enhancement and hormonal anti‑cancer activity, making it useful in oncology settings. However, its side‑effect profile, including potential for thromboembolism and hyperglycemia, differs and must be weighed against alternatives.

Megace tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture, heat and direct sunlight, and ensure the packaging remains tightly closed until use.

Megace is taken orally, usually with food or a light snack to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water; it is not intended for crushing, chewing, or sublingual administration.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, adrenal insufficiency if the drug is stopped abruptly, severe hyperglycemia, and rare cases of hepatotoxicity. Patients should be monitored regularly for signs of these complications.

Megace is contraindicated in patients with known hypersensitivity to megestrol acetate or any excipients, those with active thromboembolic disease, uncontrolled diabetes, or severe liver impairment. It should also be avoided in individuals where hormonal therapy is contraindicated, unless a specialist determines a clear benefit.